BIOG vs. TMPL, IEM, SLPE, TFIF, MUT, AGT.LN, OCI, ICGT, MRCH, and JESC
Should you be buying The Biotech Growth Trust stock or one of its competitors? The main competitors of The Biotech Growth Trust include Temple Bar (TMPL), Impax Environmental Markets (IEM), Standard Life Private Equity Trust (SLPE), TwentyFour Income (TFIF), Murray Income Trust (MUT), AVI Global Trust (AGT.LN), Oakley Capital Investments (OCI), ICG Enterprise Trust (ICGT), The Merchants Trust (MRCH), and JPMorgan European Smaller Companies Trust (JESC). These companies are all part of the "asset management" industry.
The Biotech Growth Trust vs.
The Biotech Growth Trust (LON:BIOG) and Temple Bar (LON:TMPL) are both small-cap financial services companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings.
Temple Bar has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Temple Bar, indicating that it is currently the more affordable of the two stocks.
In the previous week, Temple Bar had 4 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 5 mentions for Temple Bar and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.63 beat Temple Bar's score of 0.76 indicating that The Biotech Growth Trust is being referred to more favorably in the media.
Temple Bar received 55 more outperform votes than The Biotech Growth Trust when rated by MarketBeat users. Likewise, 72.87% of users gave Temple Bar an outperform vote while only 64.06% of users gave The Biotech Growth Trust an outperform vote.
28.6% of The Biotech Growth Trust shares are owned by institutional investors. Comparatively, 34.5% of Temple Bar shares are owned by institutional investors. 0.7% of The Biotech Growth Trust shares are owned by insiders. Comparatively, 4.7% of Temple Bar shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
The Biotech Growth Trust has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Temple Bar has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Temple Bar has a net margin of 98.26% compared to The Biotech Growth Trust's net margin of 95.33%. The Biotech Growth Trust's return on equity of 26.96% beat Temple Bar's return on equity.
Summary
Temple Bar beats The Biotech Growth Trust on 11 of the 15 factors compared between the two stocks.
Get The Biotech Growth Trust News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Biotech Growth Trust Competitors List
Related Companies and Tools
This page (LON:BIOG) was last updated on 3/25/2025 by MarketBeat.com Staff
